Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, B-Cell × tisagenlecleucel × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 7 Recurrence 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Lymphoma, Follicular 4 Burkitt Lymphoma 4 Neoplasm, Residual 1 Lymphoma, B-Cell 1 Leukemia 1

Interventions

Cyclophosphamide 46 fludarabine 29 Rituximab 28 Doxorubicin 13 Prednisone 12 Magnetic Resonance Spectroscopy 12 fludarabine phosphate 11 Vincristine 11 Specimen Handling 11 Bendamustine Hydrochloride 10 pirtobrutinib 9 Lenalidomide 9 Etoposide 9 Biopsy 8 pembrolizumab 7 obinutuzumab 7 zanubrutinib 6 venetoclax 6 polatuzumab vedotin 5 glofitamab 5 Leukapheresis 5 Immunotherapy, Adoptive 5 tazemetostat 4 tafasitamab 4 ibrutinib 4 etoposide phosphate 4 Nivolumab 4 Injections 4 CT-P10 4 loncastuximab tesirine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04419909 2025-07-02

Retreatment With CTL019/CTL119

University of Pennsylvania

Phase 1 Not yet recruiting

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡